Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 8,865,000 shares of common stock at a price of $0.79 per share in a registered direct offering, res
September 4, 2020
· 4 min read